Lunaphore and CRO Sirona Dx Collaborate to Expand COMET™ Offerings to US-based Biotech and Biopharma Customers
23.2.2023 19:00:00 EET | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. COMET™ will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005618/en/
Lunaphore’s COMET™ platform is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible. Thanks to its versatility, COMET™ has a wide range of research applications across multiple disciplines and all stages of research and drug development.
Sirona Dx is a highly-specialized technical CRO and pioneer of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic service capabilities contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“Platform selection is one of the most important decisions to make when developing multiplexed tissue imaging panels for our clients”, said Andrew Brown, Ph.D., Chief Commercial Officer at Sirona Dx. “We are extremely pleased to partner with Lunaphore to integrate the COMET™ platform into our spatial-omics operations. The ability to select off-the-shelf, label-free primary antibodies is highly advantageous and reduces the time required to develop robust, highly reproducible assays.
“The deployment of COMET™ at Sirona Dx is particularly meaningful for Lunaphore as it helps to address the large demand from US-based biotech and biopharmaceutical companies to access highly reproducible hyperplex data,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “Furthermore, Sirona Dx’s CLIA certification and deep understanding of pharmaceutical regulatory requirements add significant value for scientists looking to adopt spatial biology tools to accelerate translational research”.
To learn more about the COMET™ platform, please visit:
https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology with an intuitive approach. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit: www.lunaphore.com
About COMET™
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of 40 different spatial markers per automated run on a tissue slide. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About Sirona Dx
Sirona Dx is a technical CRO, founded in 2016 to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research, Sirona Dx offers specialized high complexity, single-cell services supporting exploratory biomarker programs and advanced precision medicine initiatives to deliver safer and more effective treatment solutions. Learn more at Sironadx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005618/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Andrew Brown, PhD
Chief Commercial Officer, Sirona Dx
Email: abrown@sironadx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 16:00:00 EEST | Press release
Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom